Showing 10–17 of 17 results
Liquid HALLMARK is a comprehensive liquid biopsy test that analyzes circulating tumor DNA (ctDNA) from a simple blood draw to detect and monitor cancer.
Sample Type : Serum
Methodology : Ultra-deep sequencing using Lucence’s proprietary AmpliMARK™ technology
TAT : 8-10 Days
The Oncotype DX Breast Cancer (ML) Test is a genomic assay that analyzes the activity of 21 genes in a breast cancer tumor to predict the risk of recurrence and the potential benefit of chemotherapy. Designed for early-stage, hormone receptor-positive, HER2-negative breast cancer patients, it provides a Recurrence Score® result that helps guide personalized treatment decisions. Key benefits include reducing unnecessary chemotherapy, improving patient outcomes, and offering evidence-based insights backed by extensive clinical validation.
Sample Type : Serum
Methodology : Enzyme-immunoassay
TAT : 10 Days
Sample Type : Whole Blood
Methodology : Spectrophotometry
TAT : 10 Days
The **Ros1 – Fish Test** is a highly sensitive and reliable fluorescence in situ hybridization (FISH) assay designed for the detection of **ROS1 gene rearrangements** in tumor samples. This test is crucial for identifying patients who may benefit from targeted therapies, particularly in **non-small cell lung cancer (NSCLC)**. Key features include **high specificity and accuracy**, rapid turnaround time, and **direct visualization of gene rearrangements** at the cellular level. Its benefits include **early and precise diagnosis**, enabling personalized treatment decisions and improving patient outcomes. The **unique selling point** of the Ros1 – Fish Test is its **proven clinical utility in guiding targeted therapy selection**, making it an essential tool for oncologists and pathologists in precision medicine.
The Valproic Acid (Depakin Level) Serum Test is a precise enzyme-immunoassay designed to monitor valproic acid levels in patients undergoing treatment for epilepsy, bipolar disorder, or migraine.
Sample Type : Serum
Methodology : Enzyme-immunoassay
TAT : 3 Days
Sample Type : Serum
Methodology : Enzyme-immunoassay
TAT : 10 Days
Whole Exome Sequencing (WES) is a powerful genetic testing method that sequences all protein-coding regions (exons) of the genome, covering approximately 1-2% of the DNA where most disease-causing mutations occur. It offers a cost-effective alternative to whole genome sequencing while providing high-depth coverage for accurate variant detection. WES enables the identification of genetic mutations linked to inherited disorders, cancer, and rare diseases, making it a valuable tool for clinical diagnostics, personalized medicine, and research.